trending Market Intelligence /marketintelligence/en/news-insights/trending/ZTvYaC2_b7anJ4Pap_WjFQ2 content esgSubNav
In This List

Sun Pharma FY'19 profit up 27.2% YOY

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Sun Pharma FY'19 profit up 27.2% YOY

Sun Pharmaceutical Industries Ltd. reported net profit for the fiscal year ended March 31 of 26.65 billion Indian rupees, up 27.2% from 20.96 billion rupees a year earlier.

EPS for the Mumbai-based maker of generic drugs was 11.11 rupees for the year, up from 8.73 rupees a year ago. Total revenue from operations were 290.66 billion rupees, up from 264.89 billion rupees in the previous fiscal year.

For the fourth quarter ended March 31, reported net profit was 6.36 billion rupees, down from 13.43 billion rupees a year earlier. The fourth quarter of the previous year had the one-time impact of a distribution change for the company's India business, as well as a one-time benefit of 2.59 billion rupees.

EPS for the quarter was 2.65 rupees, down from 5.60 rupees in the year-ago period.

Total revenue from operations for the fourth quarter was 71.64 billion rupees, up from 69.77 billion rupees a year earlier.

As of May 27, US$1 was equivalent to 69.50 Indian rupees.